The Lancet Psychiatry
Fecha de publicación: October 2020
DOI: https://doi.org/10.1016/S2215-0366(20)30378-3
Autores: Carsten Hjorthøj, Christine Merrild Posselt, Lone Baandrup
Background: In The Lancet Psychiatry, Tom Freeman and colleagues reported results from a first of its kind, phase 2a randomised trial on the effect of different doses of cannabidiol for the pharmacological treatment of cannabis use disorder. The trial appears to be well designed, and the authors concluded that both 400 mg and 800 mg cannabidiol were safe and more efficacious than placebo at reducing cannabis use.
